GlobeNewswire by notified

SBM Offshore nominates Øivind Tangen as member of the Management Board

Share

January 13, 2022

SBM Offshore is pleased to announce the proposed appointment of Øivind Tangen as Chief Operating Officer (COO) and member of its Management Board. Øivind Tangen (1973, Norwegian) has been working for the Company for 19 years and has a wealth of experience in engineering and operational roles, as well as in strategy and project execution. He is currently a Managing Director of the Company, responsible for SBM Offshore’s Lease and Operate segment, which includes the Company’s FPSO fleet.

Øivind Tangen holds an MSc in Naval Architecture from the Norwegian University of Science and Technology and ENSTA, Paris, as well as a Master of Management and Economics of Energy and the Environment from ENI Corporate University.

Øivind Tangen’s proposed appointment to the Management Board will be submitted for approval at the General Meeting to be held on April 6, 2022 (AGM).

The proposed appointment of Øivind Tangen to the Management Board underlines the Company’s focus on excellence in operations and project execution. At the same time, it will enable additional focus on delivery of SBM Offshore’s strategy through the energy transition.

Philippe Barril (currently COO) will be appointed Chief Transition Officer (CTO). The creation of a CTO role at the Management Board confirms the Company’s ambition to play a leading role in the energy transition. Human Resources, Legal & Compliance, Health, Safety, Security and Environment (HSSE) and some other corporate functions will report to the CTO.

Douglas Wood will continue as Chief Financial Officer. In the new set up of the Management Board, he will also assume responsibility for Communications in addition to Investor Relations.

Erik Lagendijk (1960, Chief Governance & Compliance Officer) has decided to step down from the Management Board after the AGM.

Bruno Chabas, CEO, said: “It is with great pleasure that we welcome Øivind to the Management Board. His nomination marks the quality of our pool of talent. Øivind has demonstrated his leadership over many years at SBM Offshore. By adding Øivind to the Management Board and with Philippe and Douglas taking a broader role as well, SBM Offshore is well positioned to deliver results in both our traditional business and strengthen our position in New Energies. I would like to thank Erik for his considerable contribution to SBM Offshore and in leading our commitment to do business with integrity.”

Erik Lagendijk said: “It is extremely satisfying to see that the Company has overcome its past issues and is now well positioned for the future. After 7 years on the Management Board, I welcome the change and the opportunity to hand over to the next generation.”


CorporateProfile

The Company’s main activities are the design, supply, installation, operation and the life extension of floating production solutions for the offshore energy industry over the full lifecycle. The Company is market leading in leased floating production systems, with multiple units currently in operation.

As of December 31, 2020, the Company employs approximately 4,570 people worldwide spread over offices in our key markets, operational shore bases and the offshore fleet of vessels.

SBM Offshore N.V. is a listed holding company headquartered in Amsterdam, the Netherlands. It holds direct and indirect interests in other companies.

Where references are made to SBM Offshore N.V. and /or its subsidiaries in general, or where no useful purpose is served by identifying the particular company or companies “SBM Offshore” or “the Company” are sometimes used for convenience.

For further information, please visit our website at www.sbmoffshore.com.

The Management Board
Amsterdam, the Netherlands, January 13, 2022

Financial Calendar DateYear
Full Year 2021 Earnings February 10 2022
Annual General Meeting April 6 2022
First Quarter 2022 Trading Update May 12 2022
Half Year 2022 Earnings August 4 2022
Third Quarter 2022 Trading Update November 10 2022


For further information, please contact:

Investor Relations
Bert-Jaap Dijkstra
Group Treasurer and IR

Mobile: +31 (0) 6 21 14 10 17
E-mail: bertjaap.dijkstra@sbmoffshore.com
Website: www.sbmoffshore.com

Media Relations
Vincent Kempkes
Group Communications Director

Mobile: +377 (0) 6 40 62 87 35
E-mail: vincent.kempkes@sbmoffshore.com
Website: www.sbmoffshore.com

Disclaimer

This press release contains inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation. Some of the statements contained in this release that are not historical facts are statements of future expectations and other forward-looking statements based on management’s current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance, or events to differ materially from those in such statements. Such forward-looking statements are subject to various risks and uncertainties, which may cause actual results and performance of the Company’s business to differ materially and adversely from the forward-looking statements. Certain such forward-looking statements can be identified by the use of forward-looking terminology such as “believes”, “may”, “will”, “should”, “would be”, “expects” or “anticipates” or similar expressions, or the negative thereof, or other variations thereof, or comparable terminology, or by discussions of strategy, plans, or intentions. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in this release as anticipated, believed, or expected. SBM Offshore NV does not intend, and does not assume any obligation, to update any industry information or forward-looking statements set forth in this release to reflect subsequent events or circumstances. Nothing in this press release shall be deemed an offer to sell, or a solicitation of an offer to buy, any securities.

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Mainz Biomed and Dante Genomics Announce Full Commercial Availability of ColoAlert in Italy and the United Arab Emirates16.8.2022 09:01:00 CEST | Press release

– ColoAlert to be marketed through Dante’s extensive database and sold via its region-specific, ecommerce websites – BERKELEY, Calif. and MAINZ, Germany and NEW YORK, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz'' or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, and Dante Genomics, a global leader in genomics and precision medicine, announced today the formal commencement of ColoAlert’s consumer commercial program in Italy and the United Arab Emirates (UAE). ColoAlert is Mainz’s flagship product, a highly efficacious and easy to use, at-home detection test for colorectal cancer (CRC) currently being commercialized across Europe and select international markets. With the ColoAlert test CE-IVD certified and patient collection kit CE marked to the latest IVDR requirements, ColoAlert will now be marketed through Dante’s extensive database and sold via Dante’s, region-specific, ecommerce websites. “This is

Cody Patrick Named OEM Direct Sales Manager for Nikkiso Clean Energy and Industrial Gases Group16.8.2022 09:01:00 CEST | Press release

TEMECULA, Calif., Aug. 16, 2022 (GLOBE NEWSWIRE) -- Nikkiso Cryogenic Industries’ Clean Energy & Industrial Gases Group (“Group”), a part of the Nikkiso Co., Ltd (Japan) group of companies, is pleased to announce that Cody Patrick has been named OEM Direct Sales Manager for Nikkiso ACD, a part of the Cryogenic Pumps unit of Nikkiso’s Clean Energy & Industrial Gases Group. Cody is a graduate of Texas A&M College of Engineering’s Industrial Distribution program. The combination of his education and experience with Cryogenic pumps for the industrial gases market, make him well suited to assist with growing the U.S. market. He will manage and develop business strategies and opportunities as well as assist with the development of training and educational programs for the Group’s clients. Cody will be based in Houston and report to Ian Guthrie, Business Line Manager for the Group’s Cryogenic Pumps unit. “Given Cody’s enthusiasm and understanding of the cryogenic pumps market we are excited t

Ahold Delhaize share buyback update16.8.2022 08:00:00 CEST | Press release

Zaandam, the Netherlands, August16, 2022 – Ahold Delhaize has repurchased 254,408 of its common shares in the period from August 8, 2022 up to and including August 12, 2022. The shares were repurchased at an average price of € 27.21 per share for a total consideration of € 6.9 million. These repurchases were made as part of the € 1 billion share buyback program announced on November 15, 2021. The total number of shares repurchased under this program to date is 20,621,088 common shares for a total consideration of € 561.6 million. Download the share buyback transactions excel sheet for detailed individual transaction information from https://www.aholddelhaize.com/en/investors/share-buyback-programs/2022/ This press release is issued in connection with the disclosure and reporting obligation set out in Article 2(2) of the EU Regulation that contains technical standards for buyback programs.

Sanionas Kv7-program för epilepsi avanceras till leadoptimering16.8.2022 08:00:00 CEST | Pressemelding

PRESSMEDDELANDE 16 augusti 2022 Saniona (OMX: SANION), ett biofarmaceutiskt företag med klinisk utveckling, meddelar idag att bolaget har avancerat sitt lovande Kv7-program för epilepsi till fasen leadoptimering – den sista fasen av läkemedelsupptäckt innan en klinisk kandidat väljs ut. Thomas Feldthus, VD: ”Vi tror att vi har löst knäckfrågorna för att utveckla nästa generation av läkemedelskandidater av den här klassen, och vi ser en betydande potential att ta fram nya banbrytande epilepsibehandlingar. Finansiellt kan uppsidan vara avsevärd, att döma av vissa viktiga läkemedelsavtal som nyligen slutits på Kv7-området.” Miljontals människor runt om i världen påverkas i dag av epilepsi, en sjukdom som kännetecknas av återkommande krampanfall. Det medicinska behovet är stort, eftersom omkring 30 procent av patienterna inte svarar på behandling med konventionella läkemedel mot epilepsi. Läkemedel mot kramper kan desutom ha funktionshämmande biverkningar, som ofta måste minimeras genom no

Saniona progresses its Kv7 epilepsy program into Lead Optimization16.8.2022 08:00:00 CEST | Press release

PRESS RELEASE August 16, 2022 Saniona (OMX: SANION), a clinical stage biopharmaceutical company, today announced that it has progressed its promising Kv7 epilepsy program into the Lead Optimization Phase, which is the last drug discovery phase before potential selection of a clinical candidate. Thomas Feldthus, CEO: “We believe that we have cracked the main challenges for making the next generation drug candidates of this class and see significant potential for delivering new breakthrough epilepsy treatments. The financial upside could be substantial based on very significant pharma deals recently executed in the Kv7 field”. Epilepsy, characterized by recurrent seizures, currently affects millions of people worldwide. There is a significant medical need as approximately 30% of patients are insensitive to treatment by conventional epilepsy medicines. Furthermore, anti-seizure therepy may cause disabling side effects and often require careful dose adjustment to minimize these. Kv7 ion ch